tegafur has been researched along with Kidney Failure, Chronic in 8 studies
Kidney Failure, Chronic: The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Tegafur is a well-known prodrug of 5-FU." | 1.42 | [A Case Report of Successful Chemotherapy with Tegafur/Gimeracil/Oteracil and Nab-Paclitaxel for Gastric Cancer with Chronic Renal Failure]. ( Kurashima, Y; Miyazaki, T; Ohata, K; Ohno, K; Okawa, M; Tanaka, S; Uenishi, T; Yamamoto, T, 2015) |
| "A 61-year-old man on hemodialysis due to chronic renal failure caused by diabetes mellitus was diagnosed as having ascending colon cancer with multiple liver metastases." | 1.38 | [A case of stage IV colon cancer effectively treated with tegafur uracil/calcium folinate in a patient on hemodialysis]. ( Kobayashi, M; Maeda, H; Okamoto, K; Takeshita, A, 2012) |
| " No severe adverse effects of more than grade 3 were encountered." | 1.37 | [Palliative anti-cancer chemotherapy is safely executable in a hemodialytic patient with unresectable advanced gastric cancer]. ( Hosojima, Y; Miura, T; Nakamura, J; Nakazawa, Y; Ozeki, Y; Takahashi, T; Yamada, S; Yamazaki, H; Yanagi, M, 2011) |
| " S-1 has safe and potent antitumor effects in patients with gastric cancer via these respective functions." | 1.32 | Safety and efficacy of S-1, a novel oral fluorouracil antitumor drug, for a chronic renal failure patient maintained on hemodialysis. ( Arakawa, T; Fujiwara, Y; Hamaguchi, M; Higuchi, K; Matsumoto, T; Okazaki, H; Oshitani, N; Sasaki, E; Shiba, M; Suto, R; Tanigawa, T; Tominaga, K; Watanabe, T, 2004) |
| "Mitomycin C (MMC) is an alkylating agent which has been associated with microangiopathic hemolytic anemia and acute renal failure, with an overall incidence between 2 and 10%." | 1.28 | Silent renal microangiography after mitomycin C therapy. ( Botey, A; Darnell, A; González-Clemente, JM; Poch, E; Revert, L; Torras, A, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (37.50) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yamamoto, T | 1 |
| Miyazaki, T | 1 |
| Kurashima, Y | 1 |
| Ohata, K | 1 |
| Okawa, M | 1 |
| Tanaka, S | 1 |
| Uenishi, T | 1 |
| Ohno, K | 1 |
| Miura, T | 2 |
| Hosojima, Y | 1 |
| Nakamura, J | 1 |
| Yamada, S | 1 |
| Nakazawa, Y | 1 |
| Ozeki, Y | 1 |
| Yanagi, M | 1 |
| Yamazaki, H | 1 |
| Takahashi, T | 1 |
| Okamoto, K | 1 |
| Kobayashi, M | 1 |
| Maeda, H | 1 |
| Takeshita, A | 1 |
| Tominaga, K | 1 |
| Higuchi, K | 1 |
| Okazaki, H | 1 |
| Suto, R | 1 |
| Hamaguchi, M | 1 |
| Tanigawa, T | 1 |
| Sasaki, E | 1 |
| Shiba, M | 1 |
| Watanabe, T | 1 |
| Fujiwara, Y | 1 |
| Oshitani, N | 1 |
| Matsumoto, T | 1 |
| Arakawa, T | 1 |
| Tanaka, T | 1 |
| Fujita, S | 1 |
| Tanaka, N | 2 |
| Ooka, M | 1 |
| Okajima, S | 1 |
| Sakamoto, K | 1 |
| Arita, S | 1 |
| Hisikawa, E | 1 |
| Yaguchi, H | 1 |
| Arima, H | 1 |
| Matsumoto, M | 1 |
| Hachisu, T | 1 |
| Kashiwabara, H | 1 |
| Yokoyama, T | 1 |
| Yanagisawa, T | 1 |
| Arimoto, T | 1 |
| Kishimoto, H | 1 |
| Takahashi, Y | 1 |
| Urade, M | 1 |
| Yoshioka, W | 1 |
| Poch, E | 1 |
| González-Clemente, JM | 1 |
| Torras, A | 1 |
| Darnell, A | 1 |
| Botey, A | 1 |
| Revert, L | 1 |
1 trial available for tegafur and Kidney Failure, Chronic
| Article | Year |
|---|---|
[Pharmacokinetic study of UFT in cancer patients receiving maintenance dialysis].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 1995 |
7 other studies available for tegafur and Kidney Failure, Chronic
| Article | Year |
|---|---|
[A Case Report of Successful Chemotherapy with Tegafur/Gimeracil/Oteracil and Nab-Paclitaxel for Gastric Cancer with Chronic Renal Failure].
Topics: Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Kidney | 2015 |
[Palliative anti-cancer chemotherapy is safely executable in a hemodialytic patient with unresectable advanced gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Humans; Irinotecan; K | 2011 |
[A case of stage IV colon cancer effectively treated with tegafur uracil/calcium folinate in a patient on hemodialysis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colectomy; Colonic Neoplasms; Combined Modality Ther | 2012 |
Safety and efficacy of S-1, a novel oral fluorouracil antitumor drug, for a chronic renal failure patient maintained on hemodialysis.
Topics: Administration, Oral; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Kidney | 2004 |
[TS-1 treatment for progressive gastric cancer in a patient on chronic dialysis--assessment of dosage regimen by monitoring blood concentrations of therapeutic drugs (TDM)].
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Area Under Curve; Drug Administration Schedu | 2005 |
[Dynamic change of serum UFT concentration in a patient with tongue cancer complicating chronic renal failure].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell | 1995 |
Silent renal microangiography after mitomycin C therapy.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Human | 1990 |